Rare NRG1 Fusion
Rare NRG1 Fusion Market

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers present in some solid tumors. These result in the activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. 


Rare NRG1 Fusion Epidemiological Segmentation 


The Epidemiological Segmentation of Rare NRG1 Fusion in 8MM from 2018 to 2030 is segmented into:-


  • Total Incident Cases of Rare NRG1 Fusion
  • Total Rare NRG1 Fusion Metastatic (including locally advanced) and Non-metastatic Stage-specific Cases
  • Total Treated cases of Rare NRG1 Fusion


Rare NRG1 Fusion Epidemiological Insights Observed in 2020


  • The total number of Rare NRG1 Fusion incident cases observed in the United States was 2,253.
  • The total Rare NRG1 Fusion incident cases in China were found to be 6,813.
  • The total Rare NRG1 Fusion incident cases in Japan were observed to be 1,341.
  • The total Rare NRG1 Fusion treated cases in the United Kingdom were found to be 60.
  • The total Rare NRG1 Fusion treated cases in 8MM were observed to be 1,604.


Rare NRG1 Fusion Market


The Rare NRG1 Fusion therapeutic market is expected to increase at a CAGR of 19% in the 8MM during the study period (2018–2030).


Rare NRG1 Fusion Market Drivers


  • Active research & development
  • Repurposing drugs as an attractive treatment strategy
  • Advancement of precision medicines/ tumor-agnostic approval


Rare NRG1 Fusion Market Barriers


  • Lack of approved therapies
  • Increased complexity of clinical trials
  • Limited patient enrollment in clinical trials


Rare NRG1 Fusion Emerging Drugs


The emerging drugs of the Rare NRG1 Fusion market are


  • Tarlox (Tarloxotinib Bromide)
  • MM-121 (Seribantumab)
  • Zeno (MCLA-128; Zenocutuzumab)
  • AV-203 (CAN017; ERBB3 MAb), and others


Rare NRG1 Fusion Key Players


The key players working in the Rare NRG1 Fusion market are 


  • Rain Therapeutics
  • Elevation Oncology
  • Merus
  • AVEO Oncology
  • CANbridge Pharmaceuticals, and others